Skip to main content

Table 1 Demographics, smoking history and spirometry. No statistically significant difference between study groups in within each trial

From: Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)

 

Macro -BB

Macro + BB

Statcope -BB

Statcope + BB

N

469

110

625

63

Age - years (SD)

64.6 (8.6)

67.3 (8.0)

62 (8.51)

63.4 (7.9)

Men - N (%)

273 (58.2%)

75 (67.6%)

349 (55.8%)

35 (55.6%)

Race

 % Black

16.8

11.7

20.3

25.4

 % White

79.5

82.9

77.1

73

Smoking History

 Pack years - mean (SD)

59.7 (33.7)

59.4 (28.5)

50.0 (26.3)*

49.1 (28.9)

 Current Smoker - %

22.4

21.6

30.6*

34.9

Spirometry - %

 GOLD 2

21.8

44.1

34.3

38.1

 GOLD 3

42.4

36

33.9

34.9

 GOLD 4

35.8

19.8

31.8

27

 FEV1 - Liters (SD)

1.09 (0.51)

1.31 (0.52)

1.20 (0.57)*

1.30 (0.62)

 FEV1 - mean % predicted value

38.3

46.8

41.8*

45.8

 FVC - Liters (SD)

2.61 (0.89)

2.81 (0.79)

2.68 (0.92)

2.65 (0.95)

 FVC - % predicted value

69.4

74.6

70.7

70.3

 FEV1/FVC

41.8

46.8

44.6

48.8

 Chronic Bronchitis - %

44.8

50.5

48.9

52.5

  1. * - p < 0.05 when compared with corresponding subgroup MACRO cohort